Equities analysts predict that Avenue Therapeutics, Inc. (NASDAQ:ATXI) will report earnings per share (EPS) of ($0.06) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Avenue Therapeutics’ earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.05). Avenue Therapeutics reported earnings per share of ($0.08) during the same quarter last year, which indicates a positive year over year growth rate of 25%. The company is scheduled to announce its next earnings report on Monday, May 10th.
According to Zacks, analysts expect that Avenue Therapeutics will report full-year earnings of ($0.25) per share for the current financial year, with EPS estimates ranging from ($0.30) to ($0.19). For the next fiscal year, analysts anticipate that the firm will post earnings of $0.60 per share, with EPS estimates ranging from ($1.27) to $2.46. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Avenue Therapeutics.
Avenue Therapeutics (NASDAQ:ATXI) last released its earnings results on Tuesday, March 30th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06).
A number of hedge funds and other institutional investors have recently bought and sold shares of ATXI. Morgan Stanley grew its position in Avenue Therapeutics by 270.9% in the 3rd quarter. Morgan Stanley now owns 22,706 shares of the company’s stock worth $246,000 after purchasing an additional 16,584 shares during the last quarter. National Asset Management Inc. grew its position in Avenue Therapeutics by 15.0% in the 4th quarter. National Asset Management Inc. now owns 167,787 shares of the company’s stock worth $999,000 after purchasing an additional 21,900 shares during the last quarter. BlackRock Inc. grew its position in Avenue Therapeutics by 5.5% in the 4th quarter. BlackRock Inc. now owns 361,486 shares of the company’s stock worth $2,150,000 after purchasing an additional 18,744 shares during the last quarter. Northern Trust Corp grew its position in Avenue Therapeutics by 2.1% in the 4th quarter. Northern Trust Corp now owns 82,691 shares of the company’s stock worth $492,000 after purchasing an additional 1,726 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Avenue Therapeutics during the 4th quarter valued at about $79,000. Institutional investors own 16.39% of the company’s stock.
Shares of Avenue Therapeutics stock traded down $0.26 during midday trading on Thursday, reaching $4.43. 6,093 shares of the company’s stock traded hands, compared to its average volume of 287,129. The company has a market cap of $74.19 million, a price-to-earnings ratio of -7.68 and a beta of 0.71. The company’s 50 day simple moving average is $5.72 and its 200 day simple moving average is $5.16. Avenue Therapeutics has a 52 week low of $2.85 and a 52 week high of $12.34.
About Avenue Therapeutics
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
Featured Story: Stock Selection – What is cash flow?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.